Dab hand at finances


Dab hand at finances

04.08.2016 - US- and UK-based genomics company Inivata has appointed Timothy Shannon as Chief Financial Officer. Shannon joins Inivata fom Baxano Surgical, where he held the position of CFO and treasurer.

Shannon, who holds a Bachelor of Business Administration from Appalachian State University, also worked at Talecris Biotherapeutics, Inc., Harris Wholesale, Inc. and PricewaterhouseCoopers LLP. He will be based out of of Inivata’s US Research Triangle Park office with global responsibilities for Inivata’s financial and operational management.


29.06.2016 Palma de Mallorca-based Sanifit, an expert for calcification disorders, has appointed Preston Klassen as its Chief Medical Officer. Klassen will also serve as President of Sanifit’s newly launched US subsidiary in San Diego.

© Sanifit

Klassen was most recently Executive Vice President, Head of Global Development at Orexigen Therapeutics. He previously held several positions at Amgen, Inc, including Therapeutic Area Head for Nephrology. Before that, Klassen was a faculty member in the Division of Nephrology at Duke University Medical Center. He received his M.D. from the University Of Nebraska College Of Medicine and M.H.S. degree from Duke University.


27.06.2016 Harriet Fear, CEO of not-for-profit One Nucleus, has been appointed a Member of the Order of the British Empire in the Queen’s Birthday 2016 Honours List. The award recognises her services to the life science sector.

© One Nucleus

Fear previously worked as a Diplomat with the British Foreign Office for 21 years serving in over 17 countries around the globe. Half her career was spent in the commercial field, latterly heading UK Trade & Investments’ national life sciences trade team for over 5 years. During her varied Foreign Office career she was Deputy Ambassador three times, Private Secretary to the Minister for Europe, led an evacuation of Brits out of the Congo and worked in Khymer Rouge territory with Scotland Yard on a hostage crisis.

Fear took over as Chief Executive at One Nucleus, an international membership organisation for life science and healthcare companies, in 2009 and was responsible for merging the former organisation ERBI with the London Biotechnology Network. 


24.06.2016 UK biotech Bicycle Therapeutics has established US operations in Cambridge (MA). Rosamund Deegan, appointed to the newly established role of President and Chief Business Officer, will be responsible for leading the company’s US business development and for establishing a team in the US.

© Bicycle Therapeutics

Bicycle Therapeutics is a biotechnology company developing a new class of therapeutics based on its proprietary bicyclic peptides platform, headquartered in Cambridge, UK. Deeagan joins from Trevena, where she  held the position of Senior VP Business development and Operations. Previously, she worked at GlaxoSmithKline. Deegan graduated from Cambridge University and holds an MBA from French business school INSEAD. 


22.06.2016 Manchester University spin-out C4X Discovery Holdings plc has a new CEO. UK biotech notable Clive Dix has taken over the helm of the UK drug discovery company. Dix joined C4XD as Non-Executive Chairman in October 2014 and became Executive Chairman in November 2015.

© C4X Discovery

Before that, he was the co-founder and CEIO of Convergence Pharmaceuticals, which was acquired by Biogen last year. Previously, Dix founded PowderMed, a vaccines development company. He currently serves as Chairman of Touchlight Genetics and Centauri Therapeutics, and was Chairman of the UK Bio­Industry Association from 2008-2010.


20.06.2016 After replacing several management positions over the last year, Poland’s leading generics producer Polpharma now also has a new head. Markus Sieger has succeeded Maurice Chagnaud as President of the Management Board and CEO.

© Polpharma

He has already been involved in supervision and management of Polpharma Group as a member of the Supervisory Board of Polpharma, delegated to exercise individual supervision over the company since 2013.

Sieger holds a degree in Economics from the University of Applied Sciences for Business and Administration in Zurich. He is the founder of consultancy firms Sieger & Sieger Ltd and of Consiglio SA.


17.06.2016 Research service provider Envigo has appointed Patricia Henahan as Chief Financial Officer. She has held similar roles at Eli Lilly, AstraZeneca, Medimmune and Hospira.

© Envigo

Prior to a short stint at Array Biopharma, Henahan had been VP of Finance at Hospira US. Before that, she had been CFO at iPR Pharmaceuticals, an AstraZeneca company. Henahan holds an MBA from the University of Philadelphia and a BS in Biology from the University of Notre Dame. She also served as a US Army Captain in the Medical Corps for 10 years.


13.06.2016 In early May, Alfredo Zurlo took over the role of Chief Medical Officer at Berlin-based clinical-stage immuno-oncology company Glycotope. He joins from Mologen, where he held the position of CMO, too, and was also a member of the Executive Board.

© Mologen

Zurlo held various positions at Hoffmann La Roche and Roche SA, including Senior International Medical Leader Director Oncology and Medical Director Oncology. Before that, he was a medical advisor for the European Organisation for the Research and Treatment of Cancer (EORTC). 

Zurlo completed his oncology and radio oncology training at the University of Rome.


10.06.2016 Dutch gene therapy play uniQure has nominated Jack Kaye to its Board of Directors. Kaye will also chair the uniQure’s Audit Committee.

© Dyadic International

Kaye, who holds a Bachelor of Business Administration from Baruch College in New York and is a Certified Public Accountant, is currently chairman of the Audit Committee and a member of the Compensation Committee of Dyadic International. Previously, he served as chairman of the Audit Committee of Keryx Biopharmaceuticals. From 1978 till 2006, he was a partner of international accounting, tax and consulting firm Deloitte.

uniQure is intending to transition from the current two-tier Supervisory Board and Management Board structure to a single Board of Directors with executive and non-executive members.


09.06.2016 ERS Genomics, formed to provide broad access to CRISPR/Cas9 IP, has appointed Eric Rhodes as its new CEO. He joins the company from Horizon Discovery where he held the role of Senior Vice President of R&D and Chief Technology Officer.

© ERS Genomics

Rhodes holds a degree in microbiology and immunology from the University of California, Berkeley. Over the course of his career, he held various positions focused on gene editing technologies including the positions of Director Business Development at Sigma-Aldrich and Vice President Business Development & Alliance Management at Sangamo Biosciences.

At ERS Genomics, Rhodes succeeds founder Shaun Foy, who will in turn become Chairman of the Board of Directors.


07.06.2016 In early June, the Hungarian National Association of Drugmakers (Magyosz) elected István Hodász as its general chairman. Hodász is CEO and managing director of the Egis Pharmaceuticals Plc, a unit of France's Servier.

© Egis

He replaces Erik Bogsch, the CEO of Gedeon Richter, who held the post for ten years.

Hodász, who according to Bloomberg graduated as a pharmacist from Semmelweis University and holds and MBA from Budapest Universits of Economics, worked for GlaxoSmithKline and Sanofi in the past. He joined Egis in 2006.

Vorherige Seite2/37Nächste Seite


Current issue

All issues

Product of the week


Stock list

All quotes


  • NEWRON (CH)22.65 CHF9.69%
  • VERNALIS (UK)45.00 GBP4.65%
  • KARO BIO (S)40.00 SEK4.44%


  • PROTHENA PLC (IE)50.02 USD-7.70%
  • BIONOR PHARMA (N)0.44 NOK-6.38%


  • DIAMYD MEDICAL -B- (S)7.25 SEK68.6%
  • KARO BIO (S)40.00 SEK34.2%
  • NEWRON (CH)22.65 CHF33.6%


  • BIONOR PHARMA (N)0.44 NOK-27.9%
  • NOVOZYMES (DK)284.40 DKK-14.0%
  • RENEURON (UK)2.75 GBP-12.7%


  • KARO BIO (S)40.00 SEK2497.4%
  • NICOX (F)10.26 EUR451.6%
  • SAREUM HOLDINGS (UK)0.74 GBP252.4%


  • BB BIOTECH (D)46.74 EUR-81.7%
  • EVOCUTIS (UK)0.04 GBP-78.9%

No liability assumed, Date: 24.08.2016


All Events